Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial

Christoph Röllig, Ulrich S. Schuler, Maria Gabrecht et al.|Blood|2015

Cited by 4